Moomoo AI 已提取核心信息
On December 28, 2023, Mangoceuticals, Inc. filed an amended Schedule 13D/A with the U.S. Securities and Exchange Commission, indicating a significant change in ownership by key figures. Jacob D. Cohen, the company's CEO and Chairman, and The Tiger Cub Trust reported a combined beneficial ownership of 9,775,000 shares of Mangoceuticals' common stock, representing 42.6% and 38.6% of the company respectively. This amendment follows the original Schedule 13D filed on May 3, 2023. The filing detailed the acquisition of shares by Jacob D. Cohen, which includes 1,500,000 shares with sole voting and dispositive power, and 8,275,000 shares with shared voting and dispositive power. The Tiger Cub Trust shares identical figures for shared voting and dispositive power. The filing also disclosed the grant of stock options to Cohen under the...Show More
On December 28, 2023, Mangoceuticals, Inc. filed an amended Schedule 13D/A with the U.S. Securities and Exchange Commission, indicating a significant change in ownership by key figures. Jacob D. Cohen, the company's CEO and Chairman, and The Tiger Cub Trust reported a combined beneficial ownership of 9,775,000 shares of Mangoceuticals' common stock, representing 42.6% and 38.6% of the company respectively. This amendment follows the original Schedule 13D filed on May 3, 2023. The filing detailed the acquisition of shares by Jacob D. Cohen, which includes 1,500,000 shares with sole voting and dispositive power, and 8,275,000 shares with shared voting and dispositive power. The Tiger Cub Trust shares identical figures for shared voting and dispositive power. The filing also disclosed the grant of stock options to Cohen under the company's 2022 Equity Incentive Plan, which vested immediately upon grant. The options, exercisable at prices of $0.32 and $1.10 per share, are set to expire in 2028 and 2027 respectively. The reporting persons have stated that the securities were acquired for investment purposes and may buy or sell additional securities depending on market conditions. No plans for major corporate changes or transactions were disclosed at this time.
2023年12月28日，Mangoceuticals, Inc.向美国证券交易委员会提交了经修订的附表13D/A，表明关键人物的所有权发生了重大变化。该公司首席执行官兼董事长雅各布·科恩和Tiger Cub Trust报告称，Mangoceuticals普通股的合并实益所有权为9,77.5万股，分别占该公司的42.6％和38.6％。该修正案遵循了2023年5月3日提交的最初附表13D。该文件详细介绍了雅各布·科恩对股票的收购，其中包括具有唯一投票权和处置权的1,500,000股股票，以及拥有共同投票权和处置权的8,27.5万股股票。Tiger Cub Trust在共享投票和处置权方面有相同的数...展开全部
2023年12月28日，Mangoceuticals, Inc.向美国证券交易委员会提交了经修订的附表13D/A，表明关键人物的所有权发生了重大变化。该公司首席执行官兼董事长雅各布·科恩和Tiger Cub Trust报告称，Mangoceuticals普通股的合并实益所有权为9,77.5万股，分别占该公司的42.6％和38.6％。该修正案遵循了2023年5月3日提交的最初附表13D。该文件详细介绍了雅各布·科恩对股票的收购，其中包括具有唯一投票权和处置权的1,500,000股股票，以及拥有共同投票权和处置权的8,27.5万股股票。Tiger Cub Trust在共享投票和处置权方面有相同的数字。该文件还披露了根据公司2022年股权激励计划向科恩授予股票期权的情况，该计划在授予后立即归属。这些期权可按每股0.32美元和1.10美元的价格行使，分别定于2028年和2027年到期。申报人表示，这些证券是出于投资目的收购的，可能会根据市场状况买入或卖出更多证券。目前尚未披露任何重大公司变更或交易的计划。
有用
没用